These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 30354525)

  • 1. Neprilysin Inhibition and Effects on Kidney Function and Surrogates of Cardiovascular Risk in Chronic Kidney Disease.
    James M; Manns B
    Circulation; 2018 Oct; 138(15):1515-1518. PubMed ID: 30354525
    [No Abstract]   [Full Text] [Related]  

  • 2. Effects of Sacubitril/Valsartan Versus Irbesartan in Patients With Chronic Kidney Disease.
    Haynes R; Judge PK; Staplin N; Herrington WG; Storey BC; Bethel A; Bowman L; Brunskill N; Cockwell P; Hill M; Kalra PA; McMurray JJV; Taal M; Wheeler DC; Landray MJ; Baigent C
    Circulation; 2018 Oct; 138(15):1505-1514. PubMed ID: 30002098
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Renal Effects and Associated Outcomes During Angiotensin-Neprilysin Inhibition in Heart Failure.
    Damman K; Gori M; Claggett B; Jhund PS; Senni M; Lefkowitz MP; Prescott MF; Shi VC; Rouleau JL; Swedberg K; Zile MR; Packer M; Desai AS; Solomon SD; McMurray JJV
    JACC Heart Fail; 2018 Jun; 6(6):489-498. PubMed ID: 29655829
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Angiotensin-Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction.
    Solomon SD; McMurray JJV; Anand IS; Ge J; Lam CSP; Maggioni AP; Martinez F; Packer M; Pfeffer MA; Pieske B; Redfield MM; Rouleau JL; van Veldhuisen DJ; Zannad F; Zile MR; Desai AS; Claggett B; Jhund PS; Boytsov SA; Comin-Colet J; Cleland J; Düngen HD; Goncalvesova E; Katova T; Kerr Saraiva JF; Lelonek M; Merkely B; Senni M; Shah SJ; Zhou J; Rizkala AR; Gong J; Shi VC; Lefkowitz MP;
    N Engl J Med; 2019 Oct; 381(17):1609-1620. PubMed ID: 31475794
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Neprilysin inhibition and chronic kidney disease].
    Di Lullo L; Ronco C; Bellasi A; Cozzolino M; Floccari F; Barbera V; Verdesca S; Rivera R; De Pascalis A; Mudoni A; Santoro A
    G Ital Nefrol; 2017 Sep; 34(5):102-112. PubMed ID: 28963831
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sacubitril/Valsartan to Reduce Secondary Mitral Regurgitation.
    Mullens W; Martens P
    Circulation; 2019 Mar; 139(11):1366-1370. PubMed ID: 30855999
    [No Abstract]   [Full Text] [Related]  

  • 7. Dual Angiotensin Receptor and Neprilysin Inhibition with Sacubitril/Valsartan in Chronic Systolic Heart Failure: Understanding the New PARADIGM.
    Lillyblad MP
    Ann Pharmacother; 2015 Nov; 49(11):1237-51. PubMed ID: 26175499
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sacubitril/valsartan in heart failure with reduced ejection fraction patients: Real world experience on advanced chronic kidney disease, hypotension, and dose escalation.
    Chang HY; Feng AN; Fong MC; Hsueh CW; Lai WT; Huang KC; Chong E; Chen CN; Chang HC; Yin WH
    J Cardiol; 2019 Oct; 74(4):372-380. PubMed ID: 30982680
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Angiotensin Receptor Neprilysin Inhibitor for Functional Mitral Regurgitation.
    Kang DH; Park SJ; Shin SH; Hong GR; Lee S; Kim MS; Yun SC; Song JM; Park SW; Kim JJ
    Circulation; 2019 Mar; 139(11):1354-1365. PubMed ID: 30586756
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Grey areas and open questions in neprilysin inhibition.
    Kodziszewska K; Sochanowicz B; Śmigielski W; Kruszewski M; Hryniewiecki T; Pączek L; Leszek P
    J Cardiol; 2020 Apr; 75(4):462-463. PubMed ID: 31883646
    [No Abstract]   [Full Text] [Related]  

  • 11. Response to "Grey Areas and Open Questions in Neprilysin Inhibition".
    Chang HY; Yin WH
    J Cardiol; 2020 Apr; 75(4):463-464. PubMed ID: 31882198
    [No Abstract]   [Full Text] [Related]  

  • 12. Neprilysin inhibition with sacubitril/valsartan in the treatment of heart failure: mortality bang for your buck.
    Ansara AJ; Kolanczyk DM; Koehler JM
    J Clin Pharm Ther; 2016 Apr; 41(2):119-27. PubMed ID: 26992459
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of renal function on the pharmacokinetics of LCZ696 (sacubitril/valsartan), an angiotensin receptor neprilysin inhibitor.
    Ayalasomayajula SP; Langenickel TH; Jordaan P; Zhou W; Chandra P; Albrecht D; Pal P; Rajman I; Sunkara G
    Eur J Clin Pharmacol; 2016 Sep; 72(9):1065-73. PubMed ID: 27230850
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sacubitril/Valsartan (LCZ696) in Heart Failure.
    Khder Y; Shi V; McMurray JJV; Lefkowitz MP
    Handb Exp Pharmacol; 2017; 243():133-165. PubMed ID: 28004291
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neprilysin inhibitors: A new hope to halt the diabetic cardiovascular and renal complications?
    Malek V; Gaikwad AB
    Biomed Pharmacother; 2017 Jun; 90():752-759. PubMed ID: 28419972
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The neprilysin pathway in heart failure: a review and guide on the use of sacubitril/valsartan.
    Jhund PS; McMurray JJ
    Heart; 2016 Sep; 102(17):1342-7. PubMed ID: 27207980
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of sacubitril/valsartan on neprilysin targets and the metabolism of natriuretic peptides in chronic heart failure: a mechanistic clinical study.
    Nougué H; Pezel T; Picard F; Sadoune M; Arrigo M; Beauvais F; Launay JM; Cohen-Solal A; Vodovar N; Logeart D
    Eur J Heart Fail; 2019 May; 21(5):598-605. PubMed ID: 30520545
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effect of angiotensin receptor neprilysin inhibitor, sacubitril/valsartan, on central nervous system amyloid-β concentrations and clearance in the cynomolgus monkey.
    Schoenfeld HA; West T; Verghese PB; Holubasch M; Shenoy N; Kagan D; Buono C; Zhou W; DeCristofaro M; Douville J; Goodrich GG; Mansfield K; Saravanan C; Cumin F; Webb RL; Bateman RJ
    Toxicol Appl Pharmacol; 2017 May; 323():53-65. PubMed ID: 28315356
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Disposition and metabolism of [(14)C] Sacubitril/Valsartan (formerly LCZ696) an angiotensin receptor neprilysin inhibitor, in healthy subjects.
    Flarakos J; Du Y; Bedman T; Al-Share Q; Jordaan P; Chandra P; Albrecht D; Wang L; Gu H; Einolf HJ; Huskey SE; Mangold JB
    Xenobiotica; 2016 Nov; 46(11):986-1000. PubMed ID: 26931777
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Sacubitril/Valsartan, a First-in-Class, Angiotensin Receptor Neprilysin Inhibitor (ARNI): Potential Uses in Hypertension, Heart Failure, and Beyond.
    Kario K
    Curr Cardiol Rep; 2018 Jan; 20(1):5. PubMed ID: 29374807
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.